COMPANY

Ablative Solutions

Location: Wakefield, MA · source · Nov 26, 2025

Profile checked Oct 10, 2026

Keywords: Hypertension Hypertension,Essential Alcohol

Funding and NIH signals

SEC Form D raise Raised $10.41M (Form D filed Nov 26, 2025). SEC Form D 0002080612-25-000020 (Nov 26, 2025)
Evidence (1 event)
- Nov 26, 2025 · SEC Form D 0002080612-25-000020
  Name of Issuer: Ablative Solutions, Inc.; CIK: 1535723; Address: Wakefield, MA; Submission type: D; Filing date: 2025-11-26; Industry Group: Other Health Care; Date of First Sale: 2025-11-14; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 45000000; Total Amount Sold: 10407500; Federal exemptions: 06b

Job counts as of Oct 18, 2026. All funding and NIH signals

2026-10 Trial start Phase 3: Renal Artery Denervation Assessment Without Antihypertensive Medication Regimen (RADAR) source ↗
Jul 22, 2019 Trial start Phase 3: TARGET BP I Clinical Trial source ↗
Sep 24, 2018 Trial start Phase 2: The TARGET BP OFF-MED Trial source ↗
2015-11 Trial start Not phased (device or behavioral study): The Peregrine Post-Market Study for the Treatment of Hypertension source ↗
2014-07 Trial start Not phased (device or behavioral study): The Peregrine Study: A Safety and Performance Study of Renal Denervation source ↗

2028-05 (ESTIMATED) · Phase 3 · Renal Artery Denervation Assessment Without Antihypertensive Medication Regimen (RADAR) · NCT07083765

Estimated primary completion per ClinicalTrials.gov. Dates move.

Record	Title	Phase	Status	Start	Primary completion
NCT07083765	Renal Artery Denervation Assessment Without Antihypertensive Medication Regimen (RADAR)	Phase 3	Not yet recruiting	2026-10	2028-05 (estimated)
NCT03503773	The TARGET BP OFF-MED Trial	Phase 2	Completed	Sep 24, 2018	Jan 31, 2022 (actual)
NCT02910414	TARGET BP I Clinical Trial	Phase 3	Active, not recruiting	Jul 22, 2019	2023-12 (estimated)
NCT02570113	The Peregrine Post-Market Study for the Treatment of Hypertension	Not phased (device or behavioral study)	Completed	2015-11	2019-02 (actual)
NCT02155790	The Peregrine Study: A Safety and Performance Study of Renal Denervation	Not phased (device or behavioral study)	Completed	2014-07	2016-01 (actual)